The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.
Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.
Researchers compared the effects of conventional treatment with a combination of epirubicin and mindfulness intervention on oncologic and psychologic burden in patients with urinary tract…
“Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.
Tell your members of Congress to close the loophole allowing corporate hospital systems to buy local doctor’s offices and then charge patients inflated hospital prices…
Becker’s is proud to recognize 70 outstanding chief strategy officers leading hospitals and health systems in 2024.
Data standardization and interoperability, and the automation of data acquisition and transfer for research purposes will be recurring themes throughout the agenda, as explained by…
Panelists discuss how secondary acute myeloid leukemia (AML) presents unique challenges in diagnosis, classification, and treatment due to its complex pathogenesis and evolving classification criteria.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
